Diagnostic, prognostic and predictive biomarkers in prostate cancer / / edited by Carsten Stephan.

Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example,...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Basel, Switzerland : : MDPI,, [2017]
©2017
Year of Publication:2017
Language:English
Series:International Journal of Molecular Sciences
Physical Description:1 online resource (414 pages) :; illustrations.
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993561966004498
ctrlnum (CKB)5400000000000305
(NjHacI)995400000000000305
(EXLCZ)995400000000000305
collection bib_alma
record_format marc
spelling Diagnostic, prognostic and predictive biomarkers in prostate cancer / edited by Carsten Stephan.
Basel, Switzerland : MDPI, [2017]
©2017
1 online resource (414 pages) : illustrations.
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
International Journal of Molecular Sciences
Description based on publisher supplied metadata and other sources.
Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others including several biomarker-based multivariate models. In addition to three studies and two reviews regarding PHI and other markers within this Special Issue "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer", new immunoassays with the PCa-associated aberrant glycosylation of PSA (S2,3PSA) have been published. However, it is important to know not only the diagnosis, but also the prognosis or further prediction of this very common disease. Here, several new nucleic acid or protein-based tissue biomarkers have been described. Most studies in this Special Issue used tissue microarrays and immunohistochemistry. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, represents a new area of interest for prostate cancer. Here, a very comprehensive review presents and discusses various important and promising kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications.
Includes bibliographical references.
About the Special Issue Editor.vii -- Preface to "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer" ix -- Carsten Stephan and Klaus Jung Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine Reprinted from: Int. J. Mol. Sci. 2017, 18(10), 2193; doi: 10.3390/ijms18102193.1 -- Annelies Gonnissen, Sofie Isebaert, Chad M. McKee, Ruth J. Muschel and Karin Haustermans The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 399; doi: 10.3390/ijms18020399.10 -- Shubham Dayal, Jun Zhou, Praveen Manivannan, Mohammad Adnan Siddiqui, Omaima Farid Ahmad, Matthew Clark, Sahezeel Awadia, Rafael Garcia-Mata, Lirim Shemshedini and Krishnamurthy Malathi RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 529; doi: 10.3390/ijms18030529.25 -- Xiaoyan Zhang, Hao Wang, Hua Wang, Fengjun Xiao, Prem Seth, Weidong Xu, Qinghua Jia, Chutse Wu, Yuefeng Yang and Lisheng Wang SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 808; doi: 10.3390/ijms18040808.53 -- Lorenzo Bascetta, Arianna Oliviero, Romina D'Aurizio, Monica Evangelista, Alberto Mercatanti, Marco Pellegrini, Francesca Marrocolo, Sergio Bracarda and Milena Rizzo The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance Reprinted from: Int. J. Mol. Sci. 2017, 18(7), 1512; doi: 10.3390/ijms18071512.66 -- Prakash Kulkarni and Vladimir N. Uversky Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 740; doi: 10.3390/ijms18040740.79 -- Kazuhisa Hagiwara, Yuki Tobisawa, Takatoshi Kaya, Tomonori Kaneko, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Yoshihiko Suda, Chikara Ohyama and Tohru Yoneyama Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 261; doi: 10.3390/ijms18020261.101 -- Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Shintaro Narita, Koji Mitsuzuka, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Takuya Koie, Tomonori Habuchi, Yoichi Arai and Chikara Ohyama An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 470; doi: 10.3390/ijms18020470.117 -- Frank Friedersdorff, Britt Groß, Andreas Maxeiner, Klaus Jung, Kurt Miller, Carsten Stephan, Jonas Busch and Ergin Kilic Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 488; doi: 10.3390/ijms18030488.132 -- Montserrat Ferrer-Batallé, Esther Llop, Manel Ramírez, Rosa Núria Aleixandre, Marc Saez, Josep Comet, Rafael de Llorens and Rosa Peracaula Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 845; doi: 10.3390/ijms18040845.142 -- Rhonda Daniel, Qianni Wu, Vernell Williams, Gene Clark, Georgi Guruli and Zendra Zehner A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1281; doi: 10.3390/ijms18061281.154 -- Jiun-Hung Geng, Victor C. Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy Reprinted from: Int. J. Mol. Sci. 2016, 17(12), 1970; doi: 10.3390/ijms17121970.182 -- Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Jan Schrader, Axel Semjonow and Martin Boegemann Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(9), 1520; doi: 10.3390/ijms17091520.192 -- Martin Boegemann, Katrin Schlack, Stefan Thomes, Julie Steinestel, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Aringer and Laura-Maria Krabbe The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 380; doi: 10.3390/ijms18020380.205 -- Xavier Filella and Laura Foj Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1784; doi: 10.3390/ijms17111784.217 -- Matteo Ferro, Paola Ungaro, Amelia Cimmino, Giuseppe Lucarelli, Gian Maria Busetto, Francesco Cantiello, Rocco Damiano and Daniela Terracciano Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS) Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1146; doi: 10.3390/ijms18061146.239 -- Jörgen Elgqvist Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1102; doi: 10.3390/ijms18051102.249 -- Kaile Zhang, Shukui Zhou, Leilei Wang, Jianlong Wang, Qingsong Zou, Weixin Zhao, Qiang Fu and Xiaolan Fang Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(7), 1163; doi: 10.3390/ijms17071163.302 -- Wei‐Yu Chen, Kuo‐Tai Hua, Wei‐Jiunn Lee, Yung‐Wei Lin, Yen‐Nien Liu, Chi‐Long Chen, Yu‐Ching Wen and Ming‐Hsien Chien Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2016, 17(8), 1194; doi: 10.3390/ijms17081194.316 -- Anna K. Campos, Hilde D. Hoving, Stefano Rosati, Geert J. L. H. van Leenders and Igle J. de Jong EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study Reprinted from: Int. J. Mol. Sci. 2016, 17(10), 1650; doi: 10.3390/ijms17101650.328 -- Vera Genitsch, Inti Zlobec, Roland Seiler, George N. Thalmann and Achim Fleischmann Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors Reprinted from: Int. J. Mol. Sci. 2017, 18(8), 1640; doi: 10.3390/ijms18081640.337 -- Ilka Kristiansen, Carsten Stephan, Klaus Jung, Manfred Dietel, Anja Rieger, Yuri Tolkach and Glen Kristiansen Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1151; doi: 10.3390/ijms18061151.346 -- Jochen Neuhaus, Eric Schiffer, Ferdinando Mannello, Lars‐Christian Horn, Roman Ganzer and Jens‐Uwe Stolzenburg Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer‐Associated Seminal Biomarkers-An Explorative Concept Study Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 976; doi: 10.3390/ijms18050976.354 -- Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M.
Goodman and Hirokatsu Yoshimura Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F‐Fluciclovine‐PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 934; doi: 10.3390/ijms18050934.371 -- Alison W. S. Luk, Yafeng Ma, Pei N. Ding, Francis P. Young, Wei Chua, Bavanthi Balakrishnar, Daniel T. Dransfield, Paul de Souza and Therese M. Becker CTC‐mRNA (AR‐V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1047; doi: 10.3390/ijms18051047.384 -- Thorsten H.
Ecke, Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann and Holger Gerullis Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1879; doi: 10.3390/ijms17111879.395 -- Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa and Masatsugu Iwamura Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(1), 128; doi: 10.3390/ijms18010128 405.
Prostate Cancer Diagnosis.
Stephan, Carsten, editor.
language English
format eBook
author2 Stephan, Carsten,
author_facet Stephan, Carsten,
author2_variant c s cs
author2_role TeilnehmendeR
title Diagnostic, prognostic and predictive biomarkers in prostate cancer /
spellingShingle Diagnostic, prognostic and predictive biomarkers in prostate cancer /
International Journal of Molecular Sciences
About the Special Issue Editor.vii -- Preface to "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer" ix -- Carsten Stephan and Klaus Jung Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine Reprinted from: Int. J. Mol. Sci. 2017, 18(10), 2193; doi: 10.3390/ijms18102193.1 -- Annelies Gonnissen, Sofie Isebaert, Chad M. McKee, Ruth J. Muschel and Karin Haustermans The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 399; doi: 10.3390/ijms18020399.10 -- Shubham Dayal, Jun Zhou, Praveen Manivannan, Mohammad Adnan Siddiqui, Omaima Farid Ahmad, Matthew Clark, Sahezeel Awadia, Rafael Garcia-Mata, Lirim Shemshedini and Krishnamurthy Malathi RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 529; doi: 10.3390/ijms18030529.25 -- Xiaoyan Zhang, Hao Wang, Hua Wang, Fengjun Xiao, Prem Seth, Weidong Xu, Qinghua Jia, Chutse Wu, Yuefeng Yang and Lisheng Wang SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 808; doi: 10.3390/ijms18040808.53 -- Lorenzo Bascetta, Arianna Oliviero, Romina D'Aurizio, Monica Evangelista, Alberto Mercatanti, Marco Pellegrini, Francesca Marrocolo, Sergio Bracarda and Milena Rizzo The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance Reprinted from: Int. J. Mol. Sci. 2017, 18(7), 1512; doi: 10.3390/ijms18071512.66 -- Prakash Kulkarni and Vladimir N. Uversky Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 740; doi: 10.3390/ijms18040740.79 -- Kazuhisa Hagiwara, Yuki Tobisawa, Takatoshi Kaya, Tomonori Kaneko, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Yoshihiko Suda, Chikara Ohyama and Tohru Yoneyama Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 261; doi: 10.3390/ijms18020261.101 -- Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Shintaro Narita, Koji Mitsuzuka, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Takuya Koie, Tomonori Habuchi, Yoichi Arai and Chikara Ohyama An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 470; doi: 10.3390/ijms18020470.117 -- Frank Friedersdorff, Britt Groß, Andreas Maxeiner, Klaus Jung, Kurt Miller, Carsten Stephan, Jonas Busch and Ergin Kilic Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 488; doi: 10.3390/ijms18030488.132 -- Montserrat Ferrer-Batallé, Esther Llop, Manel Ramírez, Rosa Núria Aleixandre, Marc Saez, Josep Comet, Rafael de Llorens and Rosa Peracaula Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 845; doi: 10.3390/ijms18040845.142 -- Rhonda Daniel, Qianni Wu, Vernell Williams, Gene Clark, Georgi Guruli and Zendra Zehner A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1281; doi: 10.3390/ijms18061281.154 -- Jiun-Hung Geng, Victor C. Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy Reprinted from: Int. J. Mol. Sci. 2016, 17(12), 1970; doi: 10.3390/ijms17121970.182 -- Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Jan Schrader, Axel Semjonow and Martin Boegemann Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(9), 1520; doi: 10.3390/ijms17091520.192 -- Martin Boegemann, Katrin Schlack, Stefan Thomes, Julie Steinestel, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Aringer and Laura-Maria Krabbe The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 380; doi: 10.3390/ijms18020380.205 -- Xavier Filella and Laura Foj Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1784; doi: 10.3390/ijms17111784.217 -- Matteo Ferro, Paola Ungaro, Amelia Cimmino, Giuseppe Lucarelli, Gian Maria Busetto, Francesco Cantiello, Rocco Damiano and Daniela Terracciano Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS) Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1146; doi: 10.3390/ijms18061146.239 -- Jörgen Elgqvist Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1102; doi: 10.3390/ijms18051102.249 -- Kaile Zhang, Shukui Zhou, Leilei Wang, Jianlong Wang, Qingsong Zou, Weixin Zhao, Qiang Fu and Xiaolan Fang Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(7), 1163; doi: 10.3390/ijms17071163.302 -- Wei‐Yu Chen, Kuo‐Tai Hua, Wei‐Jiunn Lee, Yung‐Wei Lin, Yen‐Nien Liu, Chi‐Long Chen, Yu‐Ching Wen and Ming‐Hsien Chien Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2016, 17(8), 1194; doi: 10.3390/ijms17081194.316 -- Anna K. Campos, Hilde D. Hoving, Stefano Rosati, Geert J. L. H. van Leenders and Igle J. de Jong EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study Reprinted from: Int. J. Mol. Sci. 2016, 17(10), 1650; doi: 10.3390/ijms17101650.328 -- Vera Genitsch, Inti Zlobec, Roland Seiler, George N. Thalmann and Achim Fleischmann Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors Reprinted from: Int. J. Mol. Sci. 2017, 18(8), 1640; doi: 10.3390/ijms18081640.337 -- Ilka Kristiansen, Carsten Stephan, Klaus Jung, Manfred Dietel, Anja Rieger, Yuri Tolkach and Glen Kristiansen Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1151; doi: 10.3390/ijms18061151.346 -- Jochen Neuhaus, Eric Schiffer, Ferdinando Mannello, Lars‐Christian Horn, Roman Ganzer and Jens‐Uwe Stolzenburg Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer‐Associated Seminal Biomarkers-An Explorative Concept Study Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 976; doi: 10.3390/ijms18050976.354 -- Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M.
Goodman and Hirokatsu Yoshimura Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F‐Fluciclovine‐PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 934; doi: 10.3390/ijms18050934.371 -- Alison W. S. Luk, Yafeng Ma, Pei N. Ding, Francis P. Young, Wei Chua, Bavanthi Balakrishnar, Daniel T. Dransfield, Paul de Souza and Therese M. Becker CTC‐mRNA (AR‐V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1047; doi: 10.3390/ijms18051047.384 -- Thorsten H.
Ecke, Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann and Holger Gerullis Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1879; doi: 10.3390/ijms17111879.395 -- Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa and Masatsugu Iwamura Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(1), 128; doi: 10.3390/ijms18010128 405.
title_full Diagnostic, prognostic and predictive biomarkers in prostate cancer / edited by Carsten Stephan.
title_fullStr Diagnostic, prognostic and predictive biomarkers in prostate cancer / edited by Carsten Stephan.
title_full_unstemmed Diagnostic, prognostic and predictive biomarkers in prostate cancer / edited by Carsten Stephan.
title_auth Diagnostic, prognostic and predictive biomarkers in prostate cancer /
title_new Diagnostic, prognostic and predictive biomarkers in prostate cancer /
title_sort diagnostic, prognostic and predictive biomarkers in prostate cancer /
series International Journal of Molecular Sciences
series2 International Journal of Molecular Sciences
publisher MDPI,
publishDate 2017
physical 1 online resource (414 pages) : illustrations.
contents About the Special Issue Editor.vii -- Preface to "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer" ix -- Carsten Stephan and Klaus Jung Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine Reprinted from: Int. J. Mol. Sci. 2017, 18(10), 2193; doi: 10.3390/ijms18102193.1 -- Annelies Gonnissen, Sofie Isebaert, Chad M. McKee, Ruth J. Muschel and Karin Haustermans The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 399; doi: 10.3390/ijms18020399.10 -- Shubham Dayal, Jun Zhou, Praveen Manivannan, Mohammad Adnan Siddiqui, Omaima Farid Ahmad, Matthew Clark, Sahezeel Awadia, Rafael Garcia-Mata, Lirim Shemshedini and Krishnamurthy Malathi RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 529; doi: 10.3390/ijms18030529.25 -- Xiaoyan Zhang, Hao Wang, Hua Wang, Fengjun Xiao, Prem Seth, Weidong Xu, Qinghua Jia, Chutse Wu, Yuefeng Yang and Lisheng Wang SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 808; doi: 10.3390/ijms18040808.53 -- Lorenzo Bascetta, Arianna Oliviero, Romina D'Aurizio, Monica Evangelista, Alberto Mercatanti, Marco Pellegrini, Francesca Marrocolo, Sergio Bracarda and Milena Rizzo The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance Reprinted from: Int. J. Mol. Sci. 2017, 18(7), 1512; doi: 10.3390/ijms18071512.66 -- Prakash Kulkarni and Vladimir N. Uversky Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 740; doi: 10.3390/ijms18040740.79 -- Kazuhisa Hagiwara, Yuki Tobisawa, Takatoshi Kaya, Tomonori Kaneko, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Yoshihiko Suda, Chikara Ohyama and Tohru Yoneyama Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 261; doi: 10.3390/ijms18020261.101 -- Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Shintaro Narita, Koji Mitsuzuka, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Takuya Koie, Tomonori Habuchi, Yoichi Arai and Chikara Ohyama An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 470; doi: 10.3390/ijms18020470.117 -- Frank Friedersdorff, Britt Groß, Andreas Maxeiner, Klaus Jung, Kurt Miller, Carsten Stephan, Jonas Busch and Ergin Kilic Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 488; doi: 10.3390/ijms18030488.132 -- Montserrat Ferrer-Batallé, Esther Llop, Manel Ramírez, Rosa Núria Aleixandre, Marc Saez, Josep Comet, Rafael de Llorens and Rosa Peracaula Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 845; doi: 10.3390/ijms18040845.142 -- Rhonda Daniel, Qianni Wu, Vernell Williams, Gene Clark, Georgi Guruli and Zendra Zehner A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1281; doi: 10.3390/ijms18061281.154 -- Jiun-Hung Geng, Victor C. Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy Reprinted from: Int. J. Mol. Sci. 2016, 17(12), 1970; doi: 10.3390/ijms17121970.182 -- Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Jan Schrader, Axel Semjonow and Martin Boegemann Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(9), 1520; doi: 10.3390/ijms17091520.192 -- Martin Boegemann, Katrin Schlack, Stefan Thomes, Julie Steinestel, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Aringer and Laura-Maria Krabbe The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 380; doi: 10.3390/ijms18020380.205 -- Xavier Filella and Laura Foj Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1784; doi: 10.3390/ijms17111784.217 -- Matteo Ferro, Paola Ungaro, Amelia Cimmino, Giuseppe Lucarelli, Gian Maria Busetto, Francesco Cantiello, Rocco Damiano and Daniela Terracciano Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS) Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1146; doi: 10.3390/ijms18061146.239 -- Jörgen Elgqvist Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1102; doi: 10.3390/ijms18051102.249 -- Kaile Zhang, Shukui Zhou, Leilei Wang, Jianlong Wang, Qingsong Zou, Weixin Zhao, Qiang Fu and Xiaolan Fang Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(7), 1163; doi: 10.3390/ijms17071163.302 -- Wei‐Yu Chen, Kuo‐Tai Hua, Wei‐Jiunn Lee, Yung‐Wei Lin, Yen‐Nien Liu, Chi‐Long Chen, Yu‐Ching Wen and Ming‐Hsien Chien Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2016, 17(8), 1194; doi: 10.3390/ijms17081194.316 -- Anna K. Campos, Hilde D. Hoving, Stefano Rosati, Geert J. L. H. van Leenders and Igle J. de Jong EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study Reprinted from: Int. J. Mol. Sci. 2016, 17(10), 1650; doi: 10.3390/ijms17101650.328 -- Vera Genitsch, Inti Zlobec, Roland Seiler, George N. Thalmann and Achim Fleischmann Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors Reprinted from: Int. J. Mol. Sci. 2017, 18(8), 1640; doi: 10.3390/ijms18081640.337 -- Ilka Kristiansen, Carsten Stephan, Klaus Jung, Manfred Dietel, Anja Rieger, Yuri Tolkach and Glen Kristiansen Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1151; doi: 10.3390/ijms18061151.346 -- Jochen Neuhaus, Eric Schiffer, Ferdinando Mannello, Lars‐Christian Horn, Roman Ganzer and Jens‐Uwe Stolzenburg Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer‐Associated Seminal Biomarkers-An Explorative Concept Study Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 976; doi: 10.3390/ijms18050976.354 -- Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M.
Goodman and Hirokatsu Yoshimura Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F‐Fluciclovine‐PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 934; doi: 10.3390/ijms18050934.371 -- Alison W. S. Luk, Yafeng Ma, Pei N. Ding, Francis P. Young, Wei Chua, Bavanthi Balakrishnar, Daniel T. Dransfield, Paul de Souza and Therese M. Becker CTC‐mRNA (AR‐V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1047; doi: 10.3390/ijms18051047.384 -- Thorsten H.
Ecke, Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann and Holger Gerullis Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1879; doi: 10.3390/ijms17111879.395 -- Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa and Masatsugu Iwamura Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(1), 128; doi: 10.3390/ijms18010128 405.
isbn 3-03842-633-4
callnumber-first R - Medicine
callnumber-subject RC - Internal Medicine
callnumber-label RC280
callnumber-sort RC 3280 P7 D534 42017
illustrated Illustrated
dewey-hundreds 600 - Technology
dewey-tens 610 - Medicine & health
dewey-ones 616 - Diseases
dewey-full 616.99463
dewey-sort 3616.99463
dewey-raw 616.99463
dewey-search 616.99463
work_keys_str_mv AT stephancarsten diagnosticprognosticandpredictivebiomarkersinprostatecancer
status_str n
ids_txt_mv (CKB)5400000000000305
(NjHacI)995400000000000305
(EXLCZ)995400000000000305
carrierType_str_mv cr
is_hierarchy_title Diagnostic, prognostic and predictive biomarkers in prostate cancer /
author2_original_writing_str_mv noLinkedField
_version_ 1764990019774185472
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02480nam a2200313 i 4500</leader><controlfield tag="001">993561966004498</controlfield><controlfield tag="005">20230324141451.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230324s2017 sz a ob 000 0 eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3-03842-633-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000000305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)995400000000000305</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000000305</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.P7</subfield><subfield code="b">.D534 2017</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99463</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Diagnostic, prognostic and predictive biomarkers in prostate cancer /</subfield><subfield code="c">edited by Carsten Stephan.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel, Switzerland :</subfield><subfield code="b">MDPI,</subfield><subfield code="c">[2017]</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (414 pages) :</subfield><subfield code="b">illustrations.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">International Journal of Molecular Sciences</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others including several biomarker-based multivariate models. In addition to three studies and two reviews regarding PHI and other markers within this Special Issue "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer", new immunoassays with the PCa-associated aberrant glycosylation of PSA (S2,3PSA) have been published. However, it is important to know not only the diagnosis, but also the prognosis or further prediction of this very common disease. Here, several new nucleic acid or protein-based tissue biomarkers have been described. Most studies in this Special Issue used tissue microarrays and immunohistochemistry. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, represents a new area of interest for prostate cancer. Here, a very comprehensive review presents and discusses various important and promising kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications.</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">About the Special Issue Editor.vii -- Preface to "Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer" ix -- Carsten Stephan and Klaus Jung Advances in Biomarkers for PCa Diagnostics and Prognostics-A Way towards Personalized Medicine Reprinted from: Int. J. Mol. Sci. 2017, 18(10), 2193; doi: 10.3390/ijms18102193.1 -- Annelies Gonnissen, Sofie Isebaert, Chad M. McKee, Ruth J. Muschel and Karin Haustermans The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 399; doi: 10.3390/ijms18020399.10 -- Shubham Dayal, Jun Zhou, Praveen Manivannan, Mohammad Adnan Siddiqui, Omaima Farid Ahmad, Matthew Clark, Sahezeel Awadia, Rafael Garcia-Mata, Lirim Shemshedini and Krishnamurthy Malathi RNase L Suppresses Androgen Receptor Signaling, Cell Migration and Matrix Metalloproteinase Activity in Prostate Cancer Cells Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 529; doi: 10.3390/ijms18030529.25 -- Xiaoyan Zhang, Hao Wang, Hua Wang, Fengjun Xiao, Prem Seth, Weidong Xu, Qinghua Jia, Chutse Wu, Yuefeng Yang and Lisheng Wang SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 808; doi: 10.3390/ijms18040808.53 -- Lorenzo Bascetta, Arianna Oliviero, Romina D'Aurizio, Monica Evangelista, Alberto Mercatanti, Marco Pellegrini, Francesca Marrocolo, Sergio Bracarda and Milena Rizzo The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance Reprinted from: Int. J. Mol. Sci. 2017, 18(7), 1512; doi: 10.3390/ijms18071512.66 -- Prakash Kulkarni and Vladimir N. Uversky Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 740; doi: 10.3390/ijms18040740.79 -- Kazuhisa Hagiwara, Yuki Tobisawa, Takatoshi Kaya, Tomonori Kaneko, Shingo Hatakeyama, Kazuyuki Mori, Yasuhiro Hashimoto, Takuya Koie, Yoshihiko Suda, Chikara Ohyama and Tohru Yoneyama Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 261; doi: 10.3390/ijms18020261.101 -- Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Shintaro Narita, Koji Mitsuzuka, Wilhelmina Duivenvoorden, Jehonathan H. Pinthus, Yasuhiro Hashimoto, Takuya Koie, Tomonori Habuchi, Yoichi Arai and Chikara Ohyama An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 470; doi: 10.3390/ijms18020470.117 -- Frank Friedersdorff, Britt Groß, Andreas Maxeiner, Klaus Jung, Kurt Miller, Carsten Stephan, Jonas Busch and Ergin Kilic Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2017, 18(3), 488; doi: 10.3390/ijms18030488.132 -- Montserrat Ferrer-Batallé, Esther Llop, Manel Ramírez, Rosa Núria Aleixandre, Marc Saez, Josep Comet, Rafael de Llorens and Rosa Peracaula Comparative Study of Blood-Based Biomarkers, α2,3-Sialic Acid PSA and PHI, for High-Risk Prostate Cancer Detection Reprinted from: Int. J. Mol. Sci. 2017, 18(4), 845; doi: 10.3390/ijms18040845.142 -- Rhonda Daniel, Qianni Wu, Vernell Williams, Gene Clark, Georgi Guruli and Zendra Zehner A Panel of MicroRNAs as Diagnostic Biomarkers for the Identification of Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1281; doi: 10.3390/ijms18061281.154 -- Jiun-Hung Geng, Victor C. Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang and Bo-Ying Bao Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy Reprinted from: Int. J. Mol. Sci. 2016, 17(12), 1970; doi: 10.3390/ijms17121970.182 -- Katrin Schlack, Laura-Maria Krabbe, Manfred Fobker, Andres Jan Schrader, Axel Semjonow and Martin Boegemann Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(9), 1520; doi: 10.3390/ijms17091520.192 -- Martin Boegemann, Katrin Schlack, Stefan Thomes, Julie Steinestel, Kambiz Rahbar, Axel Semjonow, Andres Jan Schrader, Martin Aringer and Laura-Maria Krabbe The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Reprinted from: Int. J. Mol. Sci. 2017, 18(2), 380; doi: 10.3390/ijms18020380.205 -- Xavier Filella and Laura Foj Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1784; doi: 10.3390/ijms17111784.217 -- Matteo Ferro, Paola Ungaro, Amelia Cimmino, Giuseppe Lucarelli, Gian Maria Busetto, Francesco Cantiello, Rocco Damiano and Daniela Terracciano Epigenetic Signature: A New Player as Predictor of Clinically Significant Prostate Cancer (PCa) in Patients on Active Surveillance (AS) Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1146; doi: 10.3390/ijms18061146.239 -- Jörgen Elgqvist Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1102; doi: 10.3390/ijms18051102.249 -- Kaile Zhang, Shukui Zhou, Leilei Wang, Jianlong Wang, Qingsong Zou, Weixin Zhao, Qiang Fu and Xiaolan Fang Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(7), 1163; doi: 10.3390/ijms17071163.302 -- Wei‐Yu Chen, Kuo‐Tai Hua, Wei‐Jiunn Lee, Yung‐Wei Lin, Yen‐Nien Liu, Chi‐Long Chen, Yu‐Ching Wen and Ming‐Hsien Chien Akt Activation Correlates with Snail Expression and Potentially Determines the Recurrence of Prostate Cancer in Patients at Stage T2 after a Radical Prostatectomy Reprinted from: Int. J. Mol. Sci. 2016, 17(8), 1194; doi: 10.3390/ijms17081194.316 -- Anna K. Campos, Hilde D. Hoving, Stefano Rosati, Geert J. L. H. van Leenders and Igle J. de Jong EpCAM Expression in Lymph Node and Bone Metastases of Prostate Carcinoma: A Pilot Study Reprinted from: Int. J. Mol. Sci. 2016, 17(10), 1650; doi: 10.3390/ijms17101650.328 -- Vera Genitsch, Inti Zlobec, Roland Seiler, George N. Thalmann and Achim Fleischmann Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors Reprinted from: Int. J. Mol. Sci. 2017, 18(8), 1640; doi: 10.3390/ijms18081640.337 -- Ilka Kristiansen, Carsten Stephan, Klaus Jung, Manfred Dietel, Anja Rieger, Yuri Tolkach and Glen Kristiansen Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA Reprinted from: Int. J. Mol. Sci. 2017, 18(6), 1151; doi: 10.3390/ijms18061151.346 -- Jochen Neuhaus, Eric Schiffer, Ferdinando Mannello, Lars‐Christian Horn, Roman Ganzer and Jens‐Uwe Stolzenburg Protease Expression Levels in Prostate Cancer Tissue Can Explain Prostate Cancer‐Associated Seminal Biomarkers-An Explorative Concept Study Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 976; doi: 10.3390/ijms18050976.354 -- Shuntaro Oka, Masaru Kanagawa, Yoshihiro Doi, David M. Schuster, Mark M. </subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Goodman and Hirokatsu Yoshimura Fasting Enhances the Contrast of Bone Metastatic Lesions in 18F‐Fluciclovine‐PET: Preclinical Study Using a Rat Model of Mixed Osteolytic/Osteoblastic Bone Metastases Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 934; doi: 10.3390/ijms18050934.371 -- Alison W. S. Luk, Yafeng Ma, Pei N. Ding, Francis P. Young, Wei Chua, Bavanthi Balakrishnar, Daniel T. Dransfield, Paul de Souza and Therese M. Becker CTC‐mRNA (AR‐V7) Analysis from Blood Samples-Impact of Blood Collection Tube and Storage Time Reprinted from: Int. J. Mol. Sci. 2017, 18(5), 1047; doi: 10.3390/ijms18051047.384 -- Thorsten H. </subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Ecke, Hui-Juan Huang-Tiel, Klaus Golka, Silvia Selinski, Berit Christine Geis, Stephan Koswig, Katrin Bathe, Steffen Hallmann and Holger Gerullis Prostate Specific Antigen (PSA) as Predicting Marker for Clinical Outcome and Evaluation of Early Toxicity Rate after High-Dose Rate Brachytherapy (HDR-BT) in Combination with Additional External Beam Radiation Therapy (EBRT) for High Risk Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2016, 17(11), 1879; doi: 10.3390/ijms17111879.395 -- Hideyasu Tsumura, Takefumi Satoh, Hiromichi Ishiyama, Ken-ichi Tabata, Kouji Takenaka, Akane Sekiguchi, Masaki Nakamura, Masashi Kitano, Kazushige Hayakawa and Masatsugu Iwamura Perioperative Search for Circulating Tumor Cells in Patients Undergoing Prostate Brachytherapy for Clinically Nonmetastatic Prostate Cancer Reprinted from: Int. J. Mol. Sci. 2017, 18(1), 128; doi: 10.3390/ijms18010128 405.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Prostate </subfield><subfield code="x">Cancer </subfield><subfield code="x">Diagnosis.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Stephan, Carsten,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-04-15 12:37:21 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2020-10-31 22:37:04 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338271110004498&amp;Force_direct=true</subfield><subfield code="Z">5338271110004498</subfield><subfield code="8">5338271110004498</subfield></datafield></record></collection>